Learning the lessons of failure

How to improve the economics of Life Sciences R&D

With approximately 90% of candidates entering clinical trials failing to achieve regulatory approval, understanding the reasons behind these failures is crucial for companies aiming to future-proof their product candidates.

Discover our latest whitepaper, “Learning the Lessons of Failure: How to improve the economics of Life Sciences R&D” and dive deep into eight real-world case studies that reveal the challenges and invaluable lessons learned from drug development programs. From overlooked breakthroughs to struggles at launch, we dissect the factors that can make or break a drug’s journey from pre-discovery to commercialization.

What you’ll learn:

Explore real-world examples of drugs and devices such as Bortezomib (Velcade), Exubera, Ionapegsomatropin (Sytrofa) and many more that faced hurdles in gaining regulatory approval.
Gain insights into overcoming obstacles and future-proofing product candidates.
Learn strategies for leveraging real-world data (RWD) to inform product and clinical trial design.
Understand how to accurately value product candidates to secure funding and inform pricing strategies.